SIR, Osteoarthritis and osteoporosis are disabling diseases in the elderly. Clinical observations suggest an inverse relationship between these disorders (for review see [1] ). This hypothesis is still controversial and no molecular basis for this observation has been demonstrated. Genome-wide linkage analysis and subsequent association study identified a single-nucleotide polymorphism (SNP) (Arg324Gly) in the frizzled-related protein (FRZB) gene associated with hip osteoarthritis in Caucasian females [2] and with generalized osteoarthritis at multiple sites in Caucasians [3] . The haplotype coding for substitutions of two arginines (Arg200Trp and Arg324Gly) in FRZB appears to be a strong risk factor for primary hip osteoarthritis in Caucasian females. FRZB is a secreted antagonist of Wnt signalling molecules [4] . The Wnt pathway is of critical importance in development, homeostasis and pathology [5] . Wnt signalling, in particular Wnt co-receptor LRP-5 and Wnt antagonist sFRP1, has also been associated with osteoporosis [6] [7] [8] .
Genetic differences within the Wnt pathway may provide a molecular basis for the inverse relationship between osteoarthritis and osteoporosis. We analysed two non-synonymous SNPs in FRZB in three populations: elderly female controls, females with osteoporotic hip fracture, and females with hip osteoarthritis requiring joint replacement surgery. The selection of female Caucasian patients was reported previously [9, 10] . Briefly, 76 women admitted for joint replacement surgery were included in the osteoarthritis group. In the osteoporosis group, 135 females consecutively admitted for low-trauma hip fracture were studied. Secondary osteoporosis was excluded. Elderly controls (n ¼ 245)
were women over 70 who had to be non-institutionalized, functionally independent and free from diseases or medications known to affect bone metabolism. ). This association remained significant after Bonferroni correction for multiple testing. For osteoporosis, an opposite trend was observed as only 23/133 patients carried a mutation compared with controls (64/238 controls patients) (P ¼ 0.049, Yates' 2 ) ( Table 1 ). This association did not remain significant after Bonferroni correction.
No differences were seen for the Arg324Gly SNP (Table 1 ). Combined analysis of both SNPs showed a significant difference between the groups (P ¼ 0.036, 3 Â 3 2 test) when patients and controls were stratified as carriers of none, one or two SNPs (Table 1 ). Significant differences were found between osteoarthritis and osteoporosis (P ¼ 0.009, 3 Â 2 2 test) as well as between osteoporosis patients and controls (P ¼ 0.021, 3 Â 2 2 test). The latter significance disappeared after Bonferroni correction. In the control group, no differences in bone mineral density were found between individuals carrying the variant and those with the normal allele at position 200 (Student's t-test P>0.5). The association of the Arg200Trp SNP in FZRB with hip osteoarthritis became apparent when osteoarthritis was compared with osteoporosis. We could not demonstrate a difference from controls. The small number of osteoarthritis and osteoporosis patients limits the power to detect association. Nevertheless, the careful selection of patients and the use of three groups may add sensitivity to the analysis.
We could not confirm the association of the Arg324Gly SNP with hip osteoarthritis. The differences between this study and the original report of Loughlin et al. [2] may partly relate to differences in study population. It is not clear to what extent osteoporosis patients were excluded from the control samples in the latter study [2] . In addition, there is evidence that populations from the UK and Belgium are genetically different [11] . The lack of significance may also be due to the small sample size and therefore lack of power.
These observations provide molecular support for the inverse relationship between osteoarthritis and osteoporosis. The Arg324Gly substitution in the FRZB gene results in loss of Wnt antagonism [2] . A similar or additional effect of the Arg200Trp substitution could not be demonstrated [2] . Gain-of-function mutations in the LRP5 Wnt co-receptor result in higher bone mass [6, 7] . Genetic deletion of sFRP1 in mice results in increased trabecular bone mineral density [8] . As increased Wnt signalling is associated with high bone mass, loss of function in FZRB may lead to higher bone density and be inversely associated with osteoporosis.
Overall, our results support the concept that the Wnt signalling pathway is of particular interest in both joint and bone diseases. Drug-induced systemic lupus erythematosus in ankylosing spondylitis associated with infliximab SIR, Infliximab therapy for the treatment of rheumatoid arthritis and Crohn disease has been associated with the development of polyarthritis, fever, induction of autoantibodies [antinuclear antibodies (ANA) and anti-double-stranded DNA (ds-DNA)] and dermatological events that are all compatible with systemic lupus erythematosus (SLE) [1, 2] . These symptoms have been attributed to the increasing levels of ANA induced during therapy with antitumour necrosis factor [3] . The induction of autoantibodies in the treatment of ankylosing spondylitis with infliximab has also been described, but to our knowledge it has never been associated previously with induction of a lupus-like syndrome [4, 5] .
Criteria for the diagnoses of drug-induced SLE are not well established, but it is widely accepted that there is a temporal relationship between the treatment and the symptoms. We describe the first case reported in the literature of drug-induced SLE in a patient with refractory ankylosing spondylitis, without previous peripheral joint manifestation, treated with infliximab.
A 65-yr-old woman diagnosed with ankylosing spondylitis according to the modified New York criteria [6] , a clinical course of more than 15 yr, positivity to HLA-B27 and recurrent episodes of uveitis was referred to the out-patient arthritis unit of a university hospital. Previous treatment with high doses of NSAIDs plus 2 g/day of sulphasalazine for 3 yr failed to control the symptoms. When sulphasalazine was changed to 15 mg
